VOR33

Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
18 patients (estimated)
Tags
Allogeneic Stem Cell Transplant, First In Human, Pre-Transplant
Trial Type
Treatment
Last Update
1 week ago
SparkCures ID
1279
NCT Identifier
NCT04849910

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.